Cite
MLA Citation
Rajat Bannerji et al.. “Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.” Lancet, vol. 9, no. 5, 2022, pp. e327–e339. http://access.bl.uk/ark:/81055/vdc_100153807955.0x000009